NCT04804618 · RECRUITING
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
This study collects biological samples — blood, urine, stool, saliva, and tongue coating — from people with mild cognitive impairment or Alzheimer's disease, then analyzes proteins in those samples using a laboratory technique called LC-MS/MS. The goal is to find protein patterns that might signal early disease. This is an observational study with no phase designation — no drug or treatment is being tested.
You may qualify if
- Older than 55-year-old，male or female.
- patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD
- Complete self-rating scale for memory impairment (AD-8 scale)
- Those who agree to participate in clinical research and sign informed consent.
You're excluded if
- Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia;
- Pregnant or lactating women;
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2022-11-15